BRAF and non-small cell lung carcinoma: This is in line with a recent publication which concluded that BMS-906024 not only sensitizes NSCLC to paclitaxel, but that this occurs more potently in KRAS and BRAF wildtype cancers therefore, possibly being able to predict better patient outcomes to dual combination therapy (19).